Poland: Europe’s Quiet Cannabis Giant with 105,000 Patients and 5 Tonnes Dispensed in 2025

How did Poland quietly build one of Europe’s largest medical cannabis markets — and survive a regulatory shock that cut prescriptions in half?

When most analysts discuss European cannabis, the conversation defaults to Germany’s scale, the UK’s private clinics, or the Czech Republic’s new adult-use framework. Poland rarely makes the headline. Yet in 2025, Polish pharmacies dispensed nearly 5,450 kilograms of dried cannabis flower to 105,000 individual patients â�� making it, by volume, one of the largest and most resilient medical cannabis markets on the continent.

What makes Poland’s story remarkable is not just its size but its survival. In November 2024, Polish authorities effectively banned telemedicine-first cannabis prescriptions, the model that had powered the market’s rapid expansion. Monthly prescription volumes collapsed by more than 50% within weeks. By October 2025, monthly dispensing had not only recovered â�� it surpassed the pre-ban peak for the first time, reaching a new all-time high in December.

For European investors and international operators evaluating where to deploy capital and compliance infrastructure, Poland now offers something no other market can: a fully documented regulatory shock-and-recovery cycle with granular monthly data. This article breaks down the numbers, the regulatory landscape, and what comes next.

Poland’s Medical Cannabis Programme â�� A Brief History

Poland legalized medical cannabis on 1 November 2017, when amendments to the Act on Counteracting Drug Addiction permitted herbal cannabis as a pharmaceutical raw material for preparing prescription medications. The first prescriptions were filled in 2018, making Poland one of the earlier adopters in Europe â�� ahead of the UK (2018 specialist prescriptions), France (2021 pilot), and the Czech Republic’s expanded programme.

Several features distinguish the Polish model from its European peers:

• No restrictive condition list. Unlike Germany’s pre-2024 framework or Italy’s tightly defined indications, Poland leaves prescribing decisions to physician discretion. Any doctor authorized to prescribe narcotics can prescribe cannabis for any condition they deem appropriate. In practice, chronic pain and oncological conditions account for the majority of prescriptions.
• Pharmacy-compounded magistral preparations. Most cannabis in Poland is dispensed as pharmacy-compounded products made from imported pharmaceutical raw material, not as pre-packaged finished products. This creates a unique supply chain dynamic.
• 100% out-of-pocket cost. Medical cannabis is not reimbursed by the public health system. Patients bear the full cost, which in 2025 averaged approximately 47 PLN per gram (roughly â�¬11).
• Import-dependent supply. Despite a 2022 law permitting domestic cultivation under permits from the Chief Pharmaceutical Inspector, no commercial-scale domestic production has reached the market. All cannabis sold in Poland is imported.

The 2022 amendment to the Act on Counteracting Drug Addiction authorized cultivation of non-fibrous cannabis by research institutes supervised by the Minister of Agriculture, with permits issued by the Chief Pharmaceutical Inspector. In December 2023, the Warsaw Institute of Biotechnology of the Agricultural and Food Industry received Poland’s first cultivation permit. However, as of early 2026, domestic production has not materially entered the supply chain â�� Poland remains an import market.

2025 by the Numbers â�� Poland’s Market Performance

The headline figures for 2025 tell a story of volume resilience and price compression occurring simultaneously.

The divergence between rising volume and falling revenue is the defining tension in Poland’s market. While 12% more flower reached patients than the prior year, the average implied price per gram dropped approximately 28% â�� from around 65 PLN to 47 PLN. Full-year revenue fell to roughly 253 million PLN (~â�¬60 million), a decline of about 19% from 2024’s peak.

This price compression reflects increased competition among importers, a broader product selection reaching Polish pharmacies, and the structural shift away from telemedicine platforms that had, in some cases, bundled consultation and product fees.

The Telemedicine Crisis and Recovery � A Regulatory Case Study

The most significant event in Poland’s cannabis market was the November 2024 ruling requiring in-person consultations for medical cannabis prescriptions. This effectively ended the telemedicine-first model that had powered the market’s rapid growth since 2022.

The Crash

The impact was immediate and severe:

• October 2024: Approximately 68,000 prescriptions filled â�� the market’s high-water mark
• December 2024: Approximately 28,000 prescriptions â�� a decline of more than 58% in two months
• Q1 2025: Volumes remained materially depressed as the market absorbed the regulatory shock

The Recovery

Rather than a return to the status quo, the recovery was driven by structural adaptation:

• Loosely regulated telemedicine platforms were replaced by hybrid clinic models â�� operators deployed licensed prescribers to physical locations in smaller cities, partially recreating the geographic access telemedicine had provided
• Some operators established rotating in-person clinics and partnered with existing medical facilities
• By mid-2025, monthly volumes began accelerating
• By October 2025, monthly dispensing surpassed the pre-ban peak for the first time
• December 2025 set a new all-time monthly record

For operators and investors, this cycle carries a clear lesson: markets driven primarily by regulatory arbitrage (in this case, loosely supervised telemedicine) are fragile, but underlying patient demand can sustain and rebuild a market when genuine access models replace opportunistic ones. Germany, which has been debating similar telemedicine restrictions, will be watching Poland’s data closely.

Who Supplies Poland? The Import Pipeline

Poland’s annual import limit for medical cannabis in 2025 was 20 million grams (20 tonnes), with actual dispensing of approximately 5,450 kg leaving substantial headroom for growth. All medical cannabis sold in Poland is imported, with the supply chain dominated by two countries and a handful of major players.

Origin Countries

The majority of medical flower products available on the Polish market are imported from Portugal, while the remaining share comes from Canada. However, a significant portion of Portuguese imports consists of Canadian-produced products that undergo final processing stages in Portugal before re-export â�� reflecting Portugal’s role as a European processing and distribution hub rather than a purely domestic producer.

Portugal exported over 18 tonnes of medical cannabis in 2024, a 54% year-on-year increase, with Germany accounting for nearly half of shipments, followed by Spain, Poland, the UK, and Australia. This makes Portugal a critical node in the supply chain for multiple European markets, not just Poland.

Major Suppliers

Aurora’s Q3 2025 results reported record global medical cannabis revenue of CA$76.2 million for the quarter, a 12% year-on-year increase driven primarily by Germany and Poland. The Polish market’s volume growth, even amid price compression, continues to attract major licensed producers looking to establish European footholds.

How Poland Compares to Other European Cannabis Markets

Poland’s position as Europe’s fourth-largest medical cannabis market becomes clearer when viewed alongside its continental peers. For investors and operators evaluating cross-border strategies, the comparison reveals distinct market personalities.

The Portugal Contrast

The comparison between Poland and Portugal is particularly instructive. Portugal has positioned itself as Europe’s cannabis production and export hub â�� with 61 licensed operators and over 18 tonnes exported in 2024. Yet domestic patient access in Portugal remains marginal, constrained by a strict approval system, high costs, and no public reimbursement.

Those searching for information on weed in Portugal or Portugal cannabis laws will find a market oriented almost entirely toward export rather than domestic consumption. Unlike Poland, where 105,000 patients accessed cannabis through a functioning (if imperfect) prescription system, Portugal’s domestic medical programme serves a fraction of that number. Cannabis cafes in Portugal and Portugal weed shops do not exist in any legal framework â�� despite Portugal’s well-known 2001 drug decriminalization policy, commercial cannabis sales remain prohibited. Visitors looking for weed in Lisbon will find that Portugal’s decriminalization applies to personal possession and use, not retail sales.

Poland, by contrast, has built a genuine patient-access market. The difference matters for operators: Poland offers demand-side scale, while Portugal offers supply-side infrastructure. International operators need both.

Regulatory Framework � What Operators Must Know

Understanding Poland’s regulatory architecture is essential for any company considering market entry or expansion. The framework sits within the broader Polish pharmaceutical system, with cannabis treated as a controlled pharmaceutical raw material rather than a standalone product category.

Prescribing and Dispensing

• Any physician authorized to prescribe narcotics may prescribe medical cannabis
• No official list of qualifying conditions â�� physician discretion applies
• Prescriptions must now be issued following an in-person consultation (since November 2024)
• Cannabis is dispensed through pharmacies as magistral preparations (pharmacy-compounded products)
• Prescriptions are tracked through Poland’s national e-prescription system

Import Licensing

• The Chief Pharmaceutical Inspector (GIF) issues one-off import licences for medical cannabis
• Annual import limit: 20 million grams (with a separate 50-gram limit for cannabis resin)
• All imported cannabis must meet EU-GMP standards
• Importers must hold appropriate pharmaceutical licences

Domestic Cultivation (Permitted but Not Yet Active)

• Since May 2022, cultivation of non-fibrous cannabis is permitted with a GIF permit
• Only research institutes supervised by the Minister of Agriculture may apply
• GACP and GMP standards required
• First permit issued December 2023 to the Warsaw Institute of Biotechnology
• No commercial-scale domestic production has reached the market as of early 2026

CBD Regulation � A Tightening Environment

Poland’s regulatory posture toward CBD has also shifted. In 2025, enforcement actions related to Novel Food regulations and CBD product classification signalled that the permissive environment for over-the-counter CBD products is narrowing. Operators should monitor the regulatory trajectory closely, as changes to CBD policy often precede or accompany shifts in the medical cannabis framework.

The Reimbursement Question â�� Poland’s Next Inflection Point

The single largest catalyst for Poland’s medical cannabis market would be the introduction of public reimbursement. Currently, patients pay the full cost out of pocket â�� averaging approximately 47 PLN per gram in 2025, down from 65 PLN the prior year. While price compression has improved affordability, cost remains a significant barrier to access, particularly for patients requiring chronic-use regimens.

In 2025, Poland’s Ministry of Health initiated a broad overhaul of the national reimbursement framework (Refundacja). Key proposed changes include:

• Procedural streamlining for reimbursement applications
• New "invitation" mechanisms where the Minister can prompt companies to submit reimbursement applications when patient need warrants it
• Revised pricing disclosure and negotiation mechanics
• Potential for pilot programmes or carve-outs for specific product categories

While medical cannabis is not explicitly named in the initial reform proposals, the reformed mechanisms could create a pathway � directly or indirectly � for structured evaluation of specific cannabis products, dosage forms, or patient groups. If even partial reimbursement were introduced for defined indications (e.g., chemotherapy-induced nausea, treatment-resistant epilepsy), patient volumes could increase substantially while further compressing per-gram pricing.

For context, Germany’s experience shows what reimbursement can do: statutory insurance coverage was a major factor in Germany’s medical cannabis market reaching an estimated â�¬670 million in 2025. Poland’s population of 38 million â�� larger than every European cannabis market except Germany â�� represents significant untapped potential if reimbursement barriers fall.

Market Projections and Investment Thesis

Poland’s medical cannabis market presents a nuanced investment case: strong volume fundamentals combined with pricing headwinds and regulatory uncertainty.

Bull Case

• Population scale: 38 million people â�� Europe’s fifth-largest country by population
• Volume trajectory: Dispensing volumes grew 12% in 2025 despite the telemedicine disruption, demonstrating genuine patient demand
• Reimbursement potential: Introduction of even partial public reimbursement could unlock significant patient volume, particularly for chronic pain and oncological indications
• Domestic cultivation: If commercial-scale domestic production materializes, reduced import dependency could improve margins for locally established operators
• Regulatory maturation: The telemedicine crisis and recovery demonstrated that Poland’s market can absorb and adapt to regulatory shocks

Bear Case

• Price compression: A 28% per-gram price decline in a single year erodes revenue even as volumes grow
• No reimbursement timeline: Ministry reform proposals are broad and do not specifically target medical cannabis
• Import dependency: The entire supply chain relies on foreign production, creating exposure to international trade disruptions and EU-GMP compliance chain risks
• Regulatory unpredictability: The November 2024 telemedicine ruling was implemented with minimal industry consultation, raising concerns about future surprise policy shifts

Projected Scenarios

Industry analysts have modelled three scenarios for Poland’s medical cannabis market through 2027, though detailed projections remain behind proprietary paywalls. The consensus view suggests:

• Conservative: Market stabilizes at â�¬55-65M annually with continued price compression offsetting modest volume growth
• Base case: Volumes continue growing 10-15% annually; selective reimbursement pilots begin by 2027; market reaches â�¬80-90M
• Optimistic: Broad reimbursement introduced; domestic cultivation enters supply chain; market exceeds â�¬120M by 2028

What Poland’s Experience Means for the Broader European Market

Poland’s 2024-2025 experience offers three lessons that apply across the European cannabis landscape:

1. Telemedicine is a growth accelerator, not a foundation. Markets built primarily on loosely regulated telehealth models are structurally fragile. Germany, the UK, and other markets relying heavily on digital prescribing should study Poland’s crash-and-recovery data when designing their own telemedicine guardrails.

2. Patient demand is more durable than access models. Poland lost its dominant prescribing channel overnight, yet 105,000 patients still accessed cannabis in 2025. This suggests that underlying medical demand, once established, persists through regulatory disruption � it simply finds new channels.

3. Price compression is the European norm, not the exception. Poland’s 28% per-gram price decline mirrors trends in Germany and the UK. Operators entering European markets should model their business cases on declining per-gram revenue offset by growing volume, not on maintaining premium pricing.

For international operators building European strategies, Poland belongs in the portfolio � not as the largest revenue opportunity, but as a market with genuine patient scale, a maturing regulatory framework, and a population that dwarfs most European peers.

How GrowerIQ Supports Compliance in European Medical Cannabis Markets

Operating in Poland’s medical cannabis market â�� or any European market â�� requires rigorous compliance infrastructure. Every gram dispensed through a Polish pharmacy traces back through a chain of EU-GMP certified production, cross-border import licensing, Chief Pharmaceutical Inspector oversight, and pharmacy-level compounding records. For operators supplying multiple European markets simultaneously, the compliance burden multiplies.

GrowerIQ’s seed-to-sale platform is built for exactly this complexity:

• EU-GMP Production Tracking: From cultivation through harvest, drying, and packaging, GrowerIQ maintains the batch-level documentation that EU-GMP certification requires â�� critical for any producer exporting to Poland or other European markets
• Cross-Border Lot Traceability: When the same production lot ships to Germany, Poland, and the UK under different regulatory regimes, GrowerIQ tracks jurisdiction-specific requirements, import licence numbers, and dispensing data for each market
• Regulatory Reporting: Automated data capture reduces the manual burden of generating compliance reports for multiple European regulators â�� whether it is Germany’s BfArM, Poland’s Chief Pharmaceutical Inspector, or the UK’s MHRA
• Recall Readiness: If a quality issue affects product distributed across multiple European markets, GrowerIQ enables rapid lot-level tracing to identify every affected package, the import licence it entered under, and the pharmacy or distributor that received it

For companies navigating Poland’s evolving regulatory landscape â�� from the telemedicine transition to potential reimbursement reforms â�� having a compliance platform that adapts to regulatory change is not optional. It is the cost of operating in Europe’s most dynamic medical cannabis market.

This analysis is current as of April 2026 and reflects market data through December 2025. Poland’s medical cannabis regulatory framework continues to evolve â�� operators should monitor developments from the Chief Pharmaceutical Inspector (GIF) and the Ministry of Health for updates on reimbursement reform and domestic cultivation licensing.

Sources:

• New Report: Poland Medical Cannabis Market Data Shows Full Post-Ban Recovery â�� Cannabis Health News
• Poland’s Medical Cannabis Market Surpassed Pre-Ban Volumes in 2025 â�� Business of Cannabis
• Cannabis Telemedicine: What Poland’s Market Crash and Recovery Tells Us About Regulatory Risk â�� Prohibition Partners
• Medical Cannabis in Poland 2025: Growth, Stability, and Wider Access â�� Born2Invest
• Medical Cannabis & Cannabinoid Regulation 2025 â�� Poland â�� Chambers and Partners
• Poland 2025 Drug Reimbursement Overhaul Meets Medical Cannabis â�� Cannabis Regulations AI
• Poland Medical Cannabis Legislation & Legal Status Map â�� Prohibition Partners
• Aurora Expands High-Potency Medical Flower Products in Poland â�� Cannabis Business Times
• Tilray Medical Bolsters Market Leading Position in Europe With Market Authorization in Poland â�� Tilray
• Portugal to Become the New ‘El Dorado’ of Medical Cannabis in Europe â�� Fortune
• Europe’s Medical Cannabis Market Surges Amid Regulatory Reforms â�� Cannabis Health News
• Cannabis in Poland â�� Wikipedia
• Cannabis Law and Legislation in Poland â�� CMS Expert Guides "},"caller":{"type":"direct"}}],"stop_reason":"tool_use